Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010

Current Opinion in Microbiology

Volumn 10, Issue 5, 2007, Pages 436-440

  Nordmann, Patrice ^a   Naas, Thierry ^a   Fortineau, Nicolas ^a   Poirel, Laurent ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

BACTERIAL INFECTION; COMMUNITY ACQUIRED INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HOSPITAL ACQUIRED INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; METHICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 35948972121     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2007.07.004     Document Type: Review

References (45)

1. Boyce J.M. Meticillin-resistant Staphylococcus aureus. Lancet Infect Dis 5 (2005) 653-663
2. Rice L.B. Antimicrobial resistance in Gram-positive bacteria. Am J Med 119 (2006) S11-S19
3. Apfelbaum P.C. MRSA-the tip of the iceberg. Clin Microbiol Infect 12 Suppl. 2 (2006) 3-10
4. Bootsma M.C., Diekmann O., and Bonten M.J. Controlling methicillin-resistant Staphylococcus aureus; quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci U S A 103 (2006) 5620-5625
5. Diekema D.J., and Edmond M.B. Look before you leap: active surveillance for multidrug-resistant organisms. Clin Infect Dis 44 (2007) 1101-1107
6. Bush K., Heep M., Macielag M.J., and Noel G.J. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 16 (2007) 419-429
7. Lin S.W., Carver P.L., and DePestel D.D. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 40 (2006) 449-460
8. Streit J.M., Sader H.S., Fritsche T.R., and Jones R.N. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn Microbiol Infect Dis 53 (2005) 307-310
9. Grundmann H., Aires-de-Sousa M., Boyce J., and Tiermersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368 (2006) 874-885
10. Miller L.G., Perdreau-Remington E., Rieg G., Mehdi S., Perlroth J., Bayer A.S., Tang A.W., Phung T.O., and Spellberg O. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352 (2005) 1445-1453. A seminal report on CA-MRSA infections.
11. Tristan A., Bes M., Meugnier H., Lina G., Bozdogan B., Courvalin P., Reverdy M.E., Enright M.C., Vandenesch F., and Etienne J. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 13 (2006) 594-600. An impressive piece of work on spread on CA-MRSA worldwide.
12. Diep B.A., Gill S.R., Chang R.F., Phan T.H., Chen J.H., Davidson M.G., Lin F., Lin J., Carleton H.A., Mongodin M.F., et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367 (2006) 731-739. The first complete genome sequence of CA-MRSA that details mobile resistance elements of that strain.
13. Nordmann P., and Naas T. Transmission of methicillin-resistant Staphylococcus aureus to a microbiologist. N Engl J Med 352 (2005) 1489-1490
14. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 42 Suppl 1 (2006) 25-34
15. Weigel L.M., Donlan R.M., Shin D.H., Jensen B., Clark N.C., McDougal L.K., Zhu W., Musser K.A., Thompson J., Kohlerschmidt D., et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrobial Agents Chemother 51 (2007) 231-238. An interesting study reporting presence of vancomycin-resistant S. aureus and VRE in biofilm as source of gene exchange.
16. Perichon B., and Courvalin P. Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 4281-4285
17. Leavis H.L., Bonten M.J., and Willems R.J. Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr Opin Microbiol 9 (2006) 454-460
18. Eom J.S., Hwang I.S., Hwang B.Y., Lee J.G., Lee Y.J., Cheong H.J., Park Y.H., Park S.C., and Kim W.J. Emergence of vanA genotype vancomycin-resistant Enterococci with low or moderate levels of teicoplanin Resistance in Korea. J Clin Microbiol 42 (2004) 1785-1786
19. Naas T., Fortineau N., Snanoudj R., Spicq C., Durrbach A., and Nordmann P. First nosocomial outbreak of vancomycin-resistant Enterococcus faecium expressing a vanD-like phenotype associated with a vanA genotype. J Clin Microbiol 43 (2005) 3642-3649
20. Tsigrelis C., Singh K.V., Coutinho T.D., Murray B.E., and Baddour L.M. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol 45 (2007) 631-635
21. Wang J., Soisson S.M., Young K., Shoop W., Kodali S., Galgoci A., Painter R., Parthasarathy G., Tang Y.S., Cummings R., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 (2006) 358-361
22. Navon-Venezia S., Ben-Ami R., and Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in healthcare setting. Curr Opinion Infect Dis 18 (2005) 306-313
23. Falagas M.E., and Bliziotis I.A. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era?. Int J Antimicrob Agents 29 (2007) 630-636. An excellent state-of-the-art of pandrug resistant Gram negative (Pseudomonas and Acinetobacter) and their treatment.
24. Reinhardt A., Kohler T., Wood P., Rohner P., Dumas J.L., Ricou B., and van Delden C. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother 51 (2007) 1341-1350
25. El'Garch F., Jeannot K., Hocquet D., Lianes-Barakat C., and Plesiat P. Cumulative effects of several nomenzymatic mechanisms of the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 51 (2007) 1016-1021
26. Weldhagen G.F., Poirel L., and Nordmann P. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 47 (2003) 2385-2392
27. Poirel L., Brinas L., Verlinde A., Ide L., and Nordmann P. BEL-1, a novel clavulanic-acid inhibited extended-spectrum ß-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 3743-3748
28. VEB gene from a Pseudomonas aeruginosa isolate obtained in India. Antimicrob Agents Chemother 48 (2004) 3284-3290
29. Poirel L., Weldhagen G.F., Naas T., De Champs C., Doye M.G., and Nordmann P. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 45 (2001) 2598-2603
30. Villegas M.V., Lolans K., Correa A., Kattan J.N., Lopez J.A., Quinn J.P., and Colombian Nosocomial Resistance Study Group. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother 51 (2007) 1553-1555
31. Thomson J.M., and Bonomo R.A. The threat of antibiotic resistance in Gram negative pathogenic bacteria; ß-lactams in peril. Curr Opin Microbiol 8 (2005) 518-524
32. Walsh T.R., Toleman M.A., Poirel L., and Nordmann P. Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev 18 (2005) 306-325. A complete summary of the problem of spread of metallo ß-lactamases.
33. Docquier J.D., Luzzaro F., Amicosante G., Toniolo A., and Rossolini G.M. Multidrug resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine ß-lactamase and VIM-2 metallo ß-lactamase. Emerg Infect Dis 7 (2001) 910-911
34. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 479-487
35. Yokoyama K., Doi Y., Yamane K., Kurokawa H., Shibata N., Shibavama K., Yagi T., Kato H., and Arakawa Y. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 362 (2003) 1888-1893
36. Doi Y., de Oliveira Garcia D., Adams J., and Paterson D.J. Coproduction of novel 16S rRNA methylase RmtD and metallo-β-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrobial Agents Chemother 51 (2007) 852-856. A study that reports novel unrelated resistance determinants in a single pandrug resistant isolate.
37. Kim C., Villegas-Estrada A., Hesek D., and Mobashery S. Mechanistic characterization of the bifunctional aminoglycoside-modifying enzyme AAC(3)-Ib/AAC(6′)-Ib from Pseudomonas aeruginosa. Biochemistry 46 (2007) 5270-5282. A novel resistance mechanism to aminoglycosides.
38. Pitout J.D., Chow Bl, Gregson D.B., Laupland K.B., Eslaved S., and Church D.L. Molecular epidemiology of metallo ß-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region; emergence of VIM-2 producing isolates. J Clin Microbiol 45 (2007) 294-298
39. Rossolini G.M. Redesigning β-lactams to combat resistance: summary and conclusions. Clin Microbiol Infect 2 (2007) 30-33
40. Mesaros N., Nordmann P., Plesiat P., Roussel-Delvallez M., Van Eldere J., Glupczinski Y., Van Laethem Y., Jacobs F., Lebecque P., Malfroot A., et al. Pseudomonas aeruginosa: resistance and therapeutic option at the turn of the new millennium. Clin Microbiol Infect 13 (2007) 560-578
41. Rice L.B. Unmet medical needs in antibacterial therapy. Biochem Pharmacol 71 (2006) 991-995
42. Hagen S., Habel A., and Blasi U. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Micro Drug Resist 12 (2006) 164-168
43. Quinteira S., and Peixe L. Multiniche screening reveals the clinically relevant metallo ß-lactamase VIM-2 in Pseudomonas aeruginosa far from the hospital setting; an ongoing dispersion process. Appl Environ Microbiol 72 (2006) 3743-3745
44. Toleman M.A., Bennet P.M., and Walsh T.R. ISCR elements: novel gene-capturing systems of the 21st century?. Microbiol Mol Biol Rev 70 (2006) 296-316. An outstanding review of totally novel DNA elements as a source of gene plasticity and expression.
45. Lode H. Management of serious nosocomial bacterial infections: do current therapeutic option meet the need?. Clin Microbiol Infect 11 (2005) 778-788